Elsevier

Clinical Therapeutics

Volume 17, Issue 6, November–December 1995, Pages 1147-1156
Clinical Therapeutics

Clinical Studies
Acid suppression by famotidine 20 mg twice daily or 40 mg twice daily in preventing relapse of endoscopic recurrence of erosive esophagitis

https://doi.org/10.1016/0149-2918(95)80093-XGet rights and content

Abstract

Control of esophageal acid exposure is important in treating patients with gastroesophageal reflux disease (GERD). After complete healing of esophagitis, most patients will relapse within 6 months if left untreated. This multicenter, randomized, double-masked, placebo-controlled trial, conducted in the United States, examined whether two famotidine dosing regimens are effective in extending the time in remission for patients with moderate-to-severe erosive esophagitis. Of 172 patients enrolled, 31 received placebo, 69 received famotidine 20 mg twice daily (BID), and 72 received famotidine 40 mg BID. Endoscopy was scheduled at baseline and at months 3 and 6. Patients assessed global heartburn and symptom relief at months 3 and 6 relative to the start of the study. Life table (Kaplan-Meier) relapse rates at 6 months were 22% (P < 0.001 vs placebo) for famotidine 20 mg BID, 11% (P < 0.001 vs placebo) for famotidine 40 mg BID, and 62% for placebo. Compared with placebo, patients in the famotidine groups were significantly less likely to note global symptomatic deterioration, as measured by the distribution of global assessment responses. The incidence of clinical and laboratory adverse experiences was similar among treatment groups. For maintenance treatment of GERD, famotidine 20 mg BID and 40 mg BID are more effective than placebo in extending the time in remission.

References (17)

  • DJ Hetzel et al.

    Healing and relapse of severe peptic esophagitis after treatment with omeprazole

    Gastroenterology

    (1988)
  • WC Orr et al.

    Dose-response effect of famotidine on patterns of gastro-oesophageal reflux

    Aliment Pharmacol Ther

    (1988)
  • TJ Simon et al.

    Randomized, placebo-controlled comparison of famotidine 20 mg b.d. or 40 mg b.d. in patients with erosive esophagitis

    Aliment Pharmacol Ther

    (1994)
  • GJ Wiener et al.

    Ambulatory 24-hour esophageal pH monitoring. Reproducibility and variability of pH parameter

    Dig Dis Sci

    (1988)
  • SJ Sontag

    Rolling review: Gastrooesophageal reflux disease

    Aliment Pharmacol Ther

    (1993)
  • NE Schindlbeck et al.

    Three year follow up of patients with gastroesophageal reflux disease

    Gut

    (1992)
  • GNJ Tytgat et al.

    Long-term strategy for the treatment of gastro-oesophageal reflux disease

    Gastroenterol Int

    (1991)
  • SJ Spechler

    Epidemiology and natural history of gastro-oesophageal reflux disease

    Digestion

    (1992)
There are more references available in the full text version of this article.

Cited by (12)

  • Gastroesophageal reflux

    2005, European Journal of Internal Medicine
  • Overview of medical therapy for gastroesophageal reflux disease

    1999, Gastroenterology Clinics of North America
  • Maintenance therapy of gastroesophageal reflux disease

    2010, Clinical Journal of Gastroenterology
  • An evidence-based, Latin-American consensus on gastro-oesophageal reflux disease

    2006, European Journal of Gastroenterology and Hepatology
View all citing articles on Scopus
View full text